MRT-2359 plus apalutamide for castration-resistant prostate cancer
Tests MRT-2359 with apalutamide in adults with castration-resistant prostate cancer.
Key facts
- Who runs it
- Monte Rosa Therapeutics, Inc
- Where
- Baltimore, Charlotte, Colorado Springs, East Brunswick, Fairfax, Kansas City, Lancaster, Los Angeles, Nashville, Newport Beach, Novi, Omaha, Seattle, and West Valley City, United StatesSee the 14 sites
- Trial code
- Registry title
- Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 25 people, planned
- Started
- 18 Aug 2026
- Expected to end
- Apr 2028
- Type of study
- Interventional
- Treatments tested
- Oral MRT-2359
- Apalutamide
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with castration-resistant prostate cancer (prostate adenocarcinoma without small cell type) with androgen receptor (AR) mutations, who have had at least 1 earlier ARPi treatment.
- Age
- Over 18 years
- Sex
- Men only
- Disease stage
- Castration-resistant adenocarcinoma of the prostate without small cell histology; disease measurable per PCWG4 criteria; ECOG performance status ≤ 1 and predicted life expectancy of ≥ 3 months
- Earlier treatment
- Must have had at least 1 line of ARPi. Must have had a PARP inhibitor, or be judged unable to take it by the investigator, or have refused it. Not more than 1 prior taxane-based chemotherapy regimen for castration-resistant prostate cancer. No prior treatment with an AR degrader, opevesostat, or similar therapy. Ongoing androgen deprivation with serum testosterone < 50 ng/dL (< 1.7 nM).
- Biomarker or test result
- Androgen receptor (AR) mutations. A tumor biopsy must be provided during screening for biomarker analysis.
Main reasons for not taking part
- Chemotherapy, definitive radiation or biological cancer therapy within 21 days before the first dose
- Earlier GSPT1 degrader therapy that was stopped because of a side effect
- Stem cell transplant not fully recovered from, or allogeneic transplant within 6 months or signs of graft-versus-host disease
- Active central nervous system involvement or carcinomatous meningitis
- History of pneumonitis (non-infectious) that needed steroids, or clinically significant heart disease
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age > 18 years
- A predicted life expectancy of ≥ 3 months and an ECOG performance status ≤ 1
- Have histologically or cytologically confirmed castration-resistant adenocarcinoma of the prostate without small cell histology and with androgen receptor (AR) mutations
- Have not had prior treatment with more than 1 prior taxane-based chemotherapy regimen for castration-resistant prostate cancer
- Have no prior treatment with an AR degrader, opevesostat, or similar therapy
- Has ongoing (chemical or surgical) androgen deprivation with serum testosterone < 50 ng/dL (< 1.7 nM)
- Has received prior treatment with poly(ADP-ribose) polymerase (PARP) inhibitor, if appropriate, or deemed ineligible to receive treatment by the Investigator, or has refused PARP inhibitor treatment
- Has received prior treatment with at least 1 line of ARPi
- Have disease measurable per Prostate Cancer Working Group 4 (PCWG4) criteria, with or without measurable disease by RECIST 1.1
- Be able to provide a tumor biopsy for biomarker analysis during the Screening period
- Have adequate organ function
Who cannot take part
- • Have received prior chemotherapy, definitive radiation, or biological cancer therapy within 21 days before the first dose of study treatment or have any AEs that have failed to recover to baseline; Have received prior therapy with a GSPT1 degrader that was discontinued due to an AE; Have received prior auto-HCT and have not fully recovered from effects of the last transplant; Have received allogeneic hematopoietic stem cell transplantation within past 6 months and/or have symptoms of graft-versus-host disease; Current use of chronic systemic steroid therapy in excess of replacement doses; Have clinically active central nervous system involvement and/or carcinomatous meningitis; Have a confirmed history of (noninfectious) pneumonitis that required steroids; Clinically significant cardiac disease
Where in United States
- University of Maryland/Greenebaum Cancer CenterBaltimore, United StatesContact: Monte Rosa Therapeutics SponsorNot yet recruiting
- Levine Cancer InstituteCharlotte, United StatesContact: Monte Rosa Therapeutics SponsorNot yet recruiting
- Rocky Mountain Cancer CenterColorado Springs, United StatesContact: Monte Rosa Therapeutics SponsorNot yet recruiting
- START - New JerseyEast Brunswick, United StatesContact: Monte Rosa Therapeutics SponsorTaking people
- Virginia Cancer SpecialistsFairfax, United StatesContact: Monte Rosa Therapeutics SponsorTaking people
- Kansas University Cancer CenterKansas City, United StatesContact: Monte Rosa Therapeutics SponsorNot yet recruiting
- Lancaster UrologyLancaster, United StatesContact: Monte Rosa Therapeutics SponsorTaking people
- START - Los AngelesLos Angeles, United StatesContact: Monte Rosa Therapeutics SponsorTaking people
- Sarah Cannon Research InstituteNashville, United StatesContact: Monte Rosa Therapeutics SponsorNot yet recruiting
- Hoag Memorial Hospital PresbyterianNewport Beach, United StatesContact: Monte Rosa Therapeutics SponsorNot yet recruiting
- Henry FordNovi, United StatesContact: Monte Rosa Therapeutics SponsorNot yet recruiting
- XCancer OmahaOmaha, United StatesContact: Monte Rosa Therapeutics SponsorTaking people
- University of Washington Medical CenterSeattle, United StatesContact: Monte Rosa Therapeutics SponsorTaking people
- START Mountain RegionWest Valley City, United StatesContact: Monte Rosa Therapeutics SponsorTaking people
About the trial
What the trial wants to find out
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer.
Read full original descriptionShow less
Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.
The group in the trial
- MRT-2359 + ApalutamideTreatment being tested
Participants with castration-resistant prostate cancer will receive MRT-2359 in combination with apalutamide.
Treatment: Oral MRT-2359 and Apalutamide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer
- Plain-language title
- MRT-2359 plus apalutamide for castration-resistant prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 November 2026